Literature DB >> 30450292

The eighth TNM classification for malignant pleural mesothelioma.

Lawek Berzenji1, Paul E Van Schil1, Laurens Carp2.   

Abstract

In 2016, the International Association for the Study of Lung Cancer (IASLC) published a number of revisions of the seventh edition of the tumor, node and metastasis (TNM) classification for malignant pleural mesothelioma (MPM). The purpose was to establish a set of recommendations for the eighth edition of the TNM staging system. A large number of patients were included in the IASLC database and subsequently analysed to determine new definitions for the components of the TNM classification. A number of important changes were introduced for the T component. Survival analysis of the different T categories showed no significant difference in categories T1a and T1b. This has resulted in a collapse of categories T1a and T1b into one category T1. In addition, tumor thickness was also significantly associated with overall survival. The descriptors for the N components have been redefined as well for the eighth TNM classification. A major revision is the removal of category N3 in the N component. Both intrapleural and extrapleural (N1 and N2 in the seventh edition) are now combined into a single category N1. Lymph nodes that were previously categorized as N3 are now considered N2. For the M component, no redefinition has been published. However, a recommendation has been made to only consider M1 involvement as stage IV disease. This is in contrast to the seventh edition in which T4 and N3 disease were considered stage IV as well. In conclusion, a number of important revisions for the eighth TNM classification of MPM have been published as a result of this IASLC project. This type of large-scale and international joint efforts are key in establishing effective staging systems. Research into using tumor thickness as a prognostic instrument will be an important part of any future editions of the TNM classification.

Entities:  

Keywords:  Mesothelioma; staging; tumor, node and metastasis (TNM)

Year:  2018        PMID: 30450292      PMCID: PMC6204412          DOI: 10.21037/tlcr.2018.07.05

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


  24 in total

1.  Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?

Authors:  T Frauenfelder; M Tutic; W Weder; R P Götti; R A Stahel; B Seifert; I Opitz
Journal:  Eur Respir J       Date:  2011-01-27       Impact factor: 16.671

2.  Analysis of risk factors for skip lymphatic metastasis and their prognostic value in operated N2 non-small-cell lung carcinoma.

Authors:  L Benoit; A Anusca; P Ortega-Deballon; N Cheynel; A Bernard; J P Favre
Journal:  Eur J Surg Oncol       Date:  2006-04-18       Impact factor: 4.424

3.  Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.

Authors:  D J Sugarbaker; R M Flores; M T Jaklitsch; W G Richards; G M Strauss; J M Corson; M M DeCamp; S J Swanson; R Bueno; J M Lukanich; E H Baldini; S J Mentzer
Journal:  J Thorac Cardiovasc Surg       Date:  1999-01       Impact factor: 5.209

4.  Robust data: the essential foundation of a revised staging system for pleural mesothelioma.

Authors:  Hedy Lee Kindler
Journal:  J Thorac Oncol       Date:  2012-11       Impact factor: 15.609

5.  Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume.

Authors:  Ritu R Gill; William G Richards; Beow Y Yeap; Shin Matsuoka; Andrea S Wolf; Victor H Gerbaudo; Raphael Bueno; David J Sugarbaker; Hiroto Hatabu
Journal:  AJR Am J Roentgenol       Date:  2012-02       Impact factor: 3.959

6.  Lymphatic drainage of the diaphragmatic pleura to the peritracheobronchial lymph nodes.

Authors:  G Okiemy; C Foucault; C Avisse; G Hidden; M Riquet
Journal:  Surg Radiol Anat       Date:  2003-04-04       Impact factor: 1.246

7.  Skip mediastinal lymph node metastasis and lung cancer: a particular N2 subgroup with a better prognosis.

Authors:  Marc Riquet; Jalal Assouad; Patrick Bagan; Christophe Foucault; Françoise Le Pimpec Barthes; Antoine Dujon; Claire Danel
Journal:  Ann Thorac Surg       Date:  2005-01       Impact factor: 4.330

8.  A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.

Authors:  V W Rusch
Journal:  Chest       Date:  1995-10       Impact factor: 9.410

9.  The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma.

Authors:  David Rice; Kari Chansky; Anna Nowak; Harvey Pass; Hedy Kindler; Lynn Shemanski; Isabelle Opitz; Sergi Call; Seiki Hasegawa; Kemp Kernstine; Cansel Atinkaya; Federico Rea; Philippe Nafteux; Valerie W Rusch
Journal:  J Thorac Oncol       Date:  2016-09-26       Impact factor: 15.609

10.  Lymph node involvement and metastatic lymph node ratio influence the survival of malignant pleural mesothelioma: a French multicenter retrospective study.

Authors:  Ilir Hysi; Françoise Le Pimpec-Barthes; Marco Alifano; Nicolas Venissac; Jérôme Mouroux; Jean-François Regnard; Marc Riquet; Henri Porte
Journal:  Oncol Rep       Date:  2013-10-18       Impact factor: 3.906

View more
  12 in total

1.  The Role of Neoadjuvant Chemotherapy in Patients With Resectable Malignant Pleural Mesothelioma-An Institutional and National Analysis.

Authors:  Soraya L Voigt; Vignesh Raman; Oliver K Jawitz; Muath Bishawi; Chi-Fu Jeffrey Yang; Betty C Tong; Thomas A D'Amico; David H Harpole
Journal:  J Natl Cancer Inst       Date:  2020-11-01       Impact factor: 13.506

2.  CT for detection of malignant posterior intercostal lymph nodes in patients undergoing pre-operative staging for malignant pleural mesothelioma.

Authors:  I Berger; Scott Simpson; J S Friedberg; Melissa J Culligan; E Paul Wileyto; Evan W Alley; D Sterman; Akash M Patel; U Khalid; C B Simone; Keith A Cengel; Sharyn I Katz; L Roshkovan
Journal:  Lung Cancer       Date:  2020-12-04       Impact factor: 5.705

3.  The prognostic value of 18F-fluorodeoxyglucose positron emission tomography/ computed tomography parameters in patients with malignant pleural mesothelioma.

Authors:  Bülent Mustafa Yenigün; Yusuf Kahya; Çiğdem Soydal; Nihal Ata Tutkun; Gökhan Kocaman; Emre Muhammed Koçak; Elgin Özkan; Serpil Dizbay Sak; Ayten Kayı Cangır
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2021-01-13       Impact factor: 0.332

4.  Ki67 (MIB-1) as a Prognostic Marker for Clinical Decision Making Before Extended Pleurectomy Decortication in Malignant Pleural Mesothelioma.

Authors:  Robert A Belderbos; Alexander P W M Maat; Sara J Baart; Eva V E Madsen; Ad J J C Bogers; Robin Cornelissen; Joachim G J V Aerts; Edris A F Mahtab; Jan H von der Thüsen
Journal:  JTO Clin Res Rep       Date:  2021-02-15

5.  Novel and Future Treatment Options in Mesothelioma: A Systematic Review.

Authors:  Danijela Štrbac; Vita Dolžan
Journal:  Int J Mol Sci       Date:  2022-02-10       Impact factor: 5.923

6.  Case Report and Review of Literature: Familial Malignant Pleural Mesothelioma in a 39 Years Old Patient With an Inconclusive 18F-FDG PET/CT Result.

Authors:  Mayar Idkedek; Kareem S Tahayneh; Firas Abu-Akar; Izzeddin A Bakri
Journal:  Front Surg       Date:  2022-03-14

7.  Surgical Diagnosis of Malignant Pleural Mesothelioma: 20 Years' Experience at a High-Volume Referral Center.

Authors:  Amedeo Iaffaldano; Thomas Charrier; Filippo Lococo; Diane Damotte; Antonio Bobbio; Marco Alifano; Ludovic Fournel
Journal:  J Clin Med       Date:  2021-05-04       Impact factor: 4.241

8.  CLDN15 is a novel diagnostic marker for malignant pleural mesothelioma.

Authors:  Masayuki Watanabe; Tomohito Higashi; Kana Ozeki; Atsuko Y Higashi; Kotaro Sugimoto; Hayato Mine; Hironori Takagi; Yuki Ozaki; Satoshi Muto; Naoyuki Okabe; Yuki Matsumura; Takeo Hasegawa; Yutaka Shio; Hiroyuki Suzuki; Hideki Chiba
Journal:  Sci Rep       Date:  2021-06-15       Impact factor: 4.379

9.  Relapse Patterns and Tailored Treatment Strategies for Malignant Pleural Mesothelioma Recurrence after Multimodality Therapy.

Authors:  Alice Bellini; Andrea Dell'Amore; Stefano Terzi; Giovanni Zambello; Andrea Zuin; Giulia Pasello; Fiorella Calabrese; Marco Schiavon; Federico Rea
Journal:  J Clin Med       Date:  2021-03-08       Impact factor: 4.241

10.  High tumor cell platelet-derived growth factor receptor beta expression is associated with shorter survival in malignant pleural epithelioid mesothelioma.

Authors:  Hely Ollila; Juuso Paajanen; Henrik Wolff; Ilkka Ilonen; Eva Sutinen; Katja Välimäki; Arne Östman; Sisko Anttila; Eeva Kettunen; Jari Räsänen; Olli Kallioniemi; Marjukka Myllärniemi; Mikko I Mäyränpää; Teijo Pellinen
Journal:  J Pathol Clin Res       Date:  2021-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.